4 recruiting, 3 active not recruiting, 2 completed, 2 terminated. 8 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Active not recruiting 3, Completed 2, Recruiting 2, Terminated 1 |
| Phase 2 | 5 | Recruiting 3, Completed 1, Terminated 1 |
Follow CDX-1140: new trials by email Literature Review of CDX-1140 trials Research Report on CDX-1140
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 44 | 2026-05-27 | 2026-10-26 |
| A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) oxaliplatin, capecitabine, Keytruda - Biliary Cancer, Bile Duct Cancer | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 60 | 2024-05-08 | 2026-10-27 |
| Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab - Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 80 | 2024-03-12 | 2026-08-14 |
| Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) TCR-transduced T cells, CDX-1140, Pembrolizumab - Malignant Epithelial Neoplasms | Phase 1 | Active not recruiting | Providence Health & Services | 1 | 2023-04-03 | 2026-04-24 |
| In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Active not recruiting | University of Southern California | 14 | 2023-01-09 | 2026-06-18 |
| A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma odetiglucan, CDX-1140 - Metastatic Pancreatic Adenocarcinoma | Phase 1 | Terminated | HiberCell, Inc. | 5 | 2022-12-15 | 2024-04-10 |
| CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer PLD Chemotherapy, CDX-1140, CDX-301 - HER2-negative Breast Cancer, Metastatic Breast Cancer | Phase 1 | Recruiting | University of Texas Southwestern Medical Center | 30 | 2022-04-20 | 2026-06-17 |
| Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) TCR-transduced T cells, CDX-1140, Pembrolizumab - Malignant Epithelial Neoplasms | Phase 1 | Active not recruiting | Providence Health & Services | 24 | 2022-02-08 | 2026-04-13 |
| Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients CDX-301, CDX-1140, Research blood draw - Pancreatic Cancer, Cancer of the Pancreas | Phase 2 | Terminated | Washington University School of Medicine | 16 | 2021-08-13 | 2024-10-08 |
| Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) 6MHP, NeoAg-mBRAF, PolyICLC - Melanoma, Ocular Melanoma | Phase 1 / Phase 2 | Completed | Craig L Slingluff, Jr | 22 | 2020-09-28 | 2024-07-16 |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies CDX-1140, CDX-301, pembrolizumab - Melanoma, Non-small Cell Lung Cancer | Phase 1 | Completed | Celldex Therapeutics | 132 | 2017-12-01 | 2024-03-28 |
Breast Neoplasms (3) · Carcinoma (3) · Melanoma (3) · Bile Duct Neoplasms (2) · Fallopian Tube Neoplasms (2) · Laryngeal Neoplasms (2) · Mouth Neoplasms (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Biliary Tract Neoplasms (1) · Bone Neoplasms (1) · Carcinoma, Basal Cell (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1)
National Cancer Institute (NCI) (2) · Providence Health & Services (2) · Celldex Therapeutics (1) · Craig L Slingluff, Jr (1) · HiberCell, Inc. (1) · Roswell Park Cancer Institute (1) · University of Southern California (1) · University of Texas Southwestern Medical Center (1) · Washington University School of Medicine (1)
United States (11)
Eric Tran, PhD (2) · Rom Leidner, MD (2) · Craig L. Slingluff, Jr., MD (1) · Emese Zsiros (1) · Fumito Ito, MD (1) · Mark O'Hara (1) · Matin Imanguli (1) · Roheena Z Panni, M.D. (1) · Sangeetha Reddy (1) · Tim F Greten, M.D. (1)
K08CA267189 (1), R01CA262506 (1), UM1CA186691 (1)